Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.55 |
| ▸ | MMP14 | P50281 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812127 | 0.87 | MMP13 (0.58) | MMP13MMP14CYP3A4TP53ADAMTS4 | |
| SCHEMBL27482210 | 0.81 | MAPT (0.42) | MMP13MMP14CYP3A4MAPTRECQL | |
| SCHEMBL4815246 | 0.79 | MMP13 (0.50) | MMP13MMP14CYP3A4TP53ADAMTS4 | |
| SCHEMBL4812547 | 0.77 | MEN1 (0.42) | MMP13MMP14CYP3A4TP53MAPT | |
| SCHEMBL16495459 | 0.77 | MMP13 (0.47) | MMP13MMP14CYP3A4TP53ADAMTS4 | |
| SCHEMBL5916477 | 0.76 | MEN1 (0.45) | TP53MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL5916438 | 0.75 | MAPT (0.44) | MMP13MMP14CYP3A4TP53ADAMTS4 | |
| SCHEMBL6218902 | 0.74 | PTGDR (0.42) | ALDH1A1POLB | |
| SCHEMBL27571160 | 0.73 | ALDH1A1 (0.63) | MMP13MMP14CYP3A4ADAMTS4MAPT | |
| SCHEMBL4699547 | 0.73 | MMP13 (0.48) | MMP13MMP14CYP3A4TP53ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| EP-1109787-B1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| US-6734184-B1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | MMP13, MMP25, MMP3 | MMP13 1/4885MMP14 10/4885CYP3A4 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.